Dexcom Inc. Stock
Dexcom Inc. Stock
A loss of -2.250% shows a downward development for Dexcom Inc..
The stock is an absolute favorite of our community with 36 Buy predictions and no Sell predictions.
With a target price of 80 € there is a positive potential of 40.25% for Dexcom Inc. compared to the current price of 57.04 €.
Our community identified positive and negative aspects for Dexcom Inc. stock for the coming years. 3 users see the criterium "Worthwhile Investment for the next years" as a plus for the Dexcom Inc. stock. On the other hand our users think that "General Risks" could be a problem in the future.
Pros and Cons of Dexcom Inc. in the next few years
Pros
?
M***** P*******
?
C******** o* t** e**********
?
S********** s********
Cons
?
B****
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Dexcom Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Dexcom Inc. | -2.250% | 1.386% | 10.930% | -24.350% | -24.450% | -48.557% | -20.474% |
| Zimmer Holdings | 0.030% | -3.631% | 0.438% | -23.585% | -23.246% | -34.831% | -35.521% |
| Henry Schein Inc. | 0.090% | 4.353% | 3.756% | -10.978% | -2.278% | -16.163% | 12.959% |
| Baxter International | 0.970% | 2.437% | 1.091% | -44.662% | -41.401% | -67.338% | -75.095% |
Comments
DexCom (NASDAQ:DXCM) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
Show more
Ratings data for DXCM provided by MarketBeat
DexCom (NASDAQ:DXCM) was upgraded by analysts at Morgan Stanley from an "equal weight" rating to an "overweight" rating. They now have a $75.00 price target on the stock.
Show more
Ratings data for DXCM provided by MarketBeat
DexCom (NASDAQ:DXCM) was downgraded by analysts at Wall Street Zen from a "strong-buy" rating to a "buy" rating.
Show more
Ratings data for DXCM provided by MarketBeat
News
DexCom Stock Just Fell to a 5-Year Low. Is It a No-Brainer Buy at This Price?
It's been a tough year for DexCom (NASDAQ: DXCM), whose stock price is down 25% since the start of 2025. It's a surprising performance, given that the overall stock market has been doing well; you
1 Spectacular Growth Stock Down 20% to Buy Right Now, According to Wall Street
Since last year, DexCom (NASDAQ: DXCM) has faced a series of issues that have sunk its stock price. The medical device specialist's shares are down 20% over the trailing-12-month period and are
From Dividends to Growth: Why These 3 Stocks Stand Out in 2025
It's rare for an attractive dividend stock also to have growth potential. Most leading dividend distributors have moved past their high-growth days and have transitioned into stable, mature
